Exhibit 99.1
Sucampo Pharmaceuticals Reports Financial Results for the Third Quarter of 2009
BETHESDA, Md.--(BUSINESS WIRE)--November 5, 2009--Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) today reported its consolidated financial results for the quarter and nine months ended September 30, 2009.
Financial Highlights of the Quarter:
- Product royalty revenue from sales of Amitiza® (lubiprostone) in the U.S. for the third quarter of 2009 was $9.4 million compared to $7.7 million during the prior year period. Product royalty revenues had been negatively impacted in the third quarter of 2008, as $1.9 million of revenue was recognized in the second quarter of 2008 from the initial stocking of Amitiza (8 mcg) for irritable bowel syndrome with constipation (IBS-C).
- Net sales of Amitiza, as reported by our collaboration partner Takeda Pharmaceutical Company (Takeda), for the third quarter of 2009 grew to $52.0 million, or by 2.4%, compared to $50.8 million the prior year period.
- Sucampo reported a net loss of $0.1 million, or $0.00 per diluted share, in the third quarter of 2009 compared to net loss of $2.4 million, or $0.06 per diluted share, in the prior year period. This favorable change is primarily attributable to increased research and development and product royalty revenues, decreased research and development expenses and a change in Sucampo’s taxable position.
- The income (loss) before income taxes for each of Sucampo’s reportable segments for the third quarter of 2009 was: a pre-tax income of $3.6 million from Sucampo Pharma Americas; a pre-tax loss of $1.5 million from Sucampo Pharma Europe; and a pre-tax loss of $0.7 million from Sucampo Pharma Asia. These results compare with losses before income taxes for the third quarter of 2008 of $2.8 million, $0.5 million and $0.9 million, respectively.
- Sucampo’s consolidated cash, cash equivalents and investments increased to $123.6 million as of September 30, 2009, from $121.5 million at December 31, 2008. The increase is mainly attributable to payments received under the Abbott Japan agreement, partially offset by the upfront payment of $3.0 million to R-Tech Ueno Ltd. for the U.S. and Canadian rights to Rescula. Sucampo had no debt as of September 30, 2009.
Operational Update:
- In October 2009, Sucampo Pharmaceuticals, Inc. announced that William L. Ashton, Dean of the Mayes College of Healthcare Business and Policy, at the University of the Sciences in Philadelphia, Pennsylvania, had been appointed to the Board of Directors. Prior to joining the university in 2005, Mr. Ashton held a number of senior executive positions at Amgen Inc., including Business Unit Vice President/General Manager of Corporate Accounts and Vice President of Commercial and Government Affairs.
- In August 2009, Sucampo Pharma Asia completed enrollment into its open-label phase 3 safety trial and, in October 2009, Sucampo Pharma Asia completed enrollment into the pivotal phase 3 efficacy trial of lubiprostone for chronic idiopathic constipation (CIC) in Japan.
- In September 2009, Sucampo Pharma Europe announced the withdrawal of its European marketing authorization application (MAA) for lubiprostone, 24 mcg, for the treatment of CIC. The decision to withdraw the MAA was strategic, based on lubiprostone’s projected commercial position in the global market.
- In July 2009, Sucampo Pharma Americas reported top-line results from two identically-designed phase 3 placebo-controlled pivotal clinical trials of lubiprostone (24 mcg, twice daily) for the management of opioid-induced bowel dysfunction (OBD) in subjects with chronic, non-cancer pain. In one trial, the primary endpoint of a statistically significant change from baseline in the frequency of spontaneous bowel movements (SBMs) was met when lubiprostone was compared to placebo. The other trial did not achieve statistical significance for the same primary endpoint. In both trials, a post-hoc sub-analysis showed that subjects on methadone treatment regimens who were randomized to receive lubiprostone showed a lower SBM response when compared to lubiprostone subjects treated with other opioid medications. The fully-enrolled, long-term, follow-on, open-label safety study of lubiprostone in OBD subjects remains ongoing, and Sucampo continues to expect to report data from this study in late 2009. Sucampo anticipates submitting data from these trials to the FDA in 2010.
- In July 2009, Sucampo Pharma Americas reported top-line results from its phase 2 clinical trial of orally administered cobiprostone for the prevention of gastric ulcers and other gastrointestinal injuries in patients treated with non-steroidal anti-inflammatory drugs (NSAID). Cobiprostone patients experienced an overall statistically significant reduction in the number of gastric erosions through the treatment period of twelve weeks compared to placebo patients. In addition, the high-dose cobiprostone group experienced a 50.0% reduction in the overall incidence of gastric ulcers when compared to patients taking placebo.
“We continue our review of Takeda’s performance regarding the disappointing sales of Amitiza and possible methods to revitalize growth for the product,” said Ryuji Ueno, M.D., Ph.D., Ph.D., Co-Founder, Chairman and Chief Executive Officer. “In the meantime, we continue to push forward in clinical development of Amitiza in other geographies and for other indications, we are preparing for the re-launch of Rescula for glaucoma as well as pursuing Rescula for additional indications with significant market and value potential, and we are proceeding in the development of our other pipeline product candidates.”
Financial Results for the Quarter and Year-to-Date
Total revenues for the third quarter of 2009 were $17.8 million, compared to $14.5 million for the third quarter of 2008. Total revenues for the first nine months of 2009 were $51.1 million compared to $95.7 million for the first nine months of 2008. The key elements of the changes in total revenues are:
- R&D revenue for the third quarter 2009 was $7.0 million, consisting of $3.5 million recognized primarily for the phase 3 OBD trials funded by Takeda, and $3.5 million of revenue recognized from the payments received under the Abbott agreement. R&D revenue for the third quarter of 2008 was $5.4 million and included revenue recognized with respect to the development programs for Amitiza in the U.S. supported by Takeda. R&D revenue for the first nine months of 2009 was $20.0 million compared to $67.0 million for the first nine months of 2008, which included a $50.0 million milestone payment from Takeda received and recognized upon the April 2008 FDA approval of Amitiza (8 mcg) for the treatment of IBS-C in adult women.
- Product royalty revenue for the third quarter of 2009 was $9.4 million compared to $7.7 million during the third quarter of 2008. This increase is due to a large extent to the third quarter of 2008 being negatively impacted by lower shipments of Amitiza (8 mcg) subsequent to its initial stocking completed in the second quarter of 2008. We recognized approximately $1.9 million of product royalty revenue in the second quarter of 2008 relating to the initial stocking that was drawn down over the following two quarters. We note that this will affect year-over-year comparisons for the fourth quarter of 2009 as well. The increase also reflects the slight growth in net sales of Amitiza, which for the three months ended September 30, 2009 and 2008 were approximately $52.0 million and $50.8 million, respectively. Product royalty revenue during the nine months ended September 30, 2009 was $27.2 million, an increase of $2.5 million, or 10.2%, compared to $24.7 million in the prior year period.
Total operating expenses during the third quarter of 2009 were $16.4 million compared to $19.3 million during the third quarter of 2008. Total operating expenses during the nine months ended September 30, 2009 were $51.1 million compared to $62.4 million during the prior year period. The key components of the changes in operating expenses are:
- R&D expenses during the third quarter of 2009 were $7.4 million, a decrease of 35.2%, from $11.4 million during the prior year quarter. The decrease was primarily due to the completion of U.S. clinical trials of Amitiza and cobiprostone, partially offset by increased expenses from ongoing phase 3 clinical trials of lubiprostone and phase 1 trials of SPI-017 in Japanese patients. R&D expenses during the first nine months of 2009 were $27.0 million, a decrease of 24.1%, from $35.5 million during the prior year period, which included approximately $2.5 million of filing and data purchase costs for the European MAA for Amitiza in Europe.
- General and administrative (G&A) expenses during the third quarter of 2009 were $4.3 million, an increase of $0.4 million, or 11.8%, from $3.9 million during the prior year quarter, primarily due to $1.4 million in expenses incurred in the preparation and the on-going conduct of a performance audit under Sucampo’s contract with Takeda and a one-time business development effort that we elected not to pursue. The increase was partially offset by a decrease in salaries, benefits and related costs resulting from cost reduction initiatives implemented at the beginning of 2009. G&A expenses during the first nine months of 2009 were $10.7 million, an increase of $0.1 million, or 1.0%, compared to $10.6 million during the prior year period.
- Selling and marketing (S&M) expenses during the third quarter of 2009 were $3.0 million, an increase of $0.3 million, or 13.7%, as compared to $2.7 million during the prior year period, primarily resulting from a one-time expense of $0.7 million incurred upon the withdrawal of Sucampo’s European MAA. The increase was offset in part by savings from the cost reduction measures in both sales and marketing. S&M expenses during the first nine months of 2009 were $7.7 million, a decrease of $0.7 million, or 7.8%, as compared to $8.4 million during the prior year period, resulting from the cost reduction measures.
Income tax - Sucampo recorded an income tax provision of $1.5 million for the third quarter of 2009 as compared to an income tax benefit of $1.7 million for the third quarter of 2008. Sucampo recorded an income tax provision of $2.7 million for the first nine months of 2009 as compared to $7.2 million for the first nine months of 2008. The income tax benefit/provision relates mainly to the profitable results of Sucampo’s U.S. operations.
The financial results for the third quarter of 2009 of Sucampo’s reportable segments (United States, Europe and Japan), continue to reflect their respective varying stages of development:
- Sucampo Pharma Americas recorded income before taxes of $3.6 million for the third quarter of 2009 compared to a loss before taxes of $2.8 million in the third quarter of 2008. The increase was mainly due to higher product royalty revenue and decreased R&D expenses due to the completion of U.S. clinical trials of Amitiza and cobiprostone and decreased overall preclinical and basic development costs.
- Sucampo Pharma Europe reported a loss before taxes of $1.5 million for the third quarter of 2009 compared to a loss before taxes of $0.5 million in the third quarter of 2008, reflecting the expenses incurred for the European regulatory approval and pre-commercialization activities for lubiprostone in Europe.
- Sucampo Pharma Asia reported a loss before taxes of $0.7 million in the third quarter of 2009 as compared to a loss before taxes of $0.9 million during the third quarter of 2008. The results reflect the ongoing investment in the clinical program for lubiprostone and SPI-017 and the ongoing preclinical programs for other prostone-based compounds.
Sucampo’s consolidated cash, cash equivalents and investments totaled $123.6 million at September 30, 2009 as compared with $121.5 million at December 31, 2008. Sucampo Pharmaceuticals, Inc. had no debt as of September 30, 2009.
Company to Host Conference Call Today
Sucampo management will host a conference call today, November 5, 2009 at 4:30 pm Eastern Time to discuss these results. To participate on the live call, please dial 866-783-2138 (domestic) or +1-857-350-1597 (international), and provide the participant passcode 31403000, five to ten minutes ahead of the start of the call. A replay of the call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-286-8010 (domestic) or 1-617-801-6888 (international), with the passcode 52346247.
A live and archived audio webcast of the call will be available via the "For Investors" page of the Sucampo Pharmaceuticals website, www.sucampo.com. Please dial in or log on through Sucampo Pharmaceuticals' website approximately 10 minutes prior to the scheduled start time.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc., an international biopharmaceutical company based in Bethesda, Maryland, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals’ Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and currently Director and Advisor, International Business Development.
Sucampo is marketing Amitiza® (lubiprostone) 24 mcg in the U.S. for chronic idiopathic constipation in adults and Amitiza 8 mcg in the U.S. to treat irritable bowel syndrome with constipation in adult women. Sucampo also is developing the drug for additional gastrointestinal disorders with large potential markets. In addition, Sucampo has a robust pipeline of compounds with the potential to target underserved diseases affecting millions of patients worldwide. Sucampo Pharmaceuticals, Inc. has three wholly owned subsidiaries: Sucampo Pharma Europe, Ltd., located in the UK; Sucampo Pharma, Ltd., located in Japan; and, Sucampo Pharma Americas, Inc., located in Maryland. To learn more about Sucampo Pharmaceuticals and its products, visit www.sucampo.com.
Amitiza is registered trademark of Sucampo Pharmaceuticals, Inc. and Rescula is a registered trademark used under license.
Amitiza is co-marketed in the U.S. by Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Sucampo Pharmaceuticals, Inc. and its subsidiaries are forward-looking statements made under the provisions of The Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the words “project,” “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “should,” “would,” “could,” “will,” ”may” or other similar expressions. Forward-looking statements include statements about potential trial results, the potential utility of Amitiza and Rescula to treat particular indications and expected data availability, trial commencement and regulatory dates. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those described in Sucampo Pharmaceuticals’ filings with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K for the year ended December 31, 2008 and other periodic reports filed with the SEC. Any forward-looking statements in this press release represent Sucampo Pharmaceuticals’ views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Sucampo Pharmaceuticals anticipates that subsequent events and developments will cause its views to change. However, while Sucampo Pharmaceuticals may elect to update these forward-looking statements publicly at some point in the future, Sucampo Pharmaceuticals specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise.
(Financial Schedules Follow)
| |
| Sucampo Pharmaceuticals, Inc. |
| Consolidated Statements of Operations (unaudited) |
| (in thousands, except per share data) |
| | Three Months Ended | | Nine Months Ended |
| | September 30, | | September 30, |
| | 2009 | | 2008 | | 2009 | | 2008 |
| | | | | | | | |
| Revenues: | | | | | | | | |
| Research and development revenue | | $ | 7,045 | | | $ | 5,436 | | | $ | 19,966 | | | $ | 66,982 | |
| Product royalty revenue | | | 9,367 | | | | 7,718 | | | | 27,227 | | | | 24,699 | |
| Co-promotion revenue | | | 1,266 | | | | 1,185 | | | | 3,406 | | | | 3,643 | |
| Contract and collaboration revenue | | | 153 | | | | 142 | | | | 451 | | | | 425 | |
| Total revenues | | | 17,831 | | | | 14,481 | | | | 51,050 | | | | 95,749 | |
| | | | | | | | |
| Operating expenses: | | | | | | | | |
| Research and development | | | 7,383 | | | | 11,390 | | | | 26,969 | | | | 35,537 | |
| General and administrative | | | 4,317 | | | | 3,863 | | | | 10,696 | | | | 10,591 | |
| Selling and marketing | | | 3,047 | | | | 2,680 | | | | 7,747 | | | | 8,398 | |
| Milestone royalties - related parties | | | - | | | | - | | | | 875 | | | | 3,531 | |
| Product royalties - related parties | | | 1,664 | | | | 1,359 | | | | 4,837 | | | | 4,391 | |
| Total operating expenses | | | 16,411 | | | | 19,292 | | | | 51,124 | | | | 62,448 | |
| | | | | | | | |
| Income (loss) from operations | | | 1,420 | | | | (4,811 | ) | | | (74 | ) | | | 33,301 | |
| Non-operating income (expense): | | | | | | | | |
| Interest income | | | 211 | | | | 655 | | | | 742 | | | | 1,862 | |
| Other expense, net | | | (250 | ) | | | (15 | ) | | | (36 | ) | | | (16 | ) |
| Total non-operating income (expense), net | | | (39 | ) | | | 640 | | | | 706 | | | | 1,846 | |
| | | | | | | | |
| Income (loss) before income taxes | | | 1,381 | | | | (4,171 | ) | | | 632 | | | | 35,147 | |
| Income tax benefit (provision) | | | (1,469 | ) | | | 1,745 | | | | (2,733 | ) | | | (7,192 | ) |
| Net income (loss) | | $ | (88 | ) | | $ | (2,426 | ) | | $ | (2,101 | ) | | $ | 27,955 | |
| | | | | | | | |
| Net income (loss) per share: | | | | | | | | |
| Basic net income (loss) per share | | $ | - | | | $ | (0.06 | ) | | $ | (0.05 | ) | | $ | 0.67 | |
| Diluted net income (loss) per share | | $ | - | | | $ | (0.06 | ) | | $ | (0.05 | ) | | $ | 0.67 | |
| Weighted average common shares outstanding - basic | | | 41,844 | | | | 41,813 | | | | 41,844 | | | | 41,768 | |
| Weighted average common shares outstanding - diluted | | | 41,844 | | | | 41,813 | | | | 41,844 | | | | 42,022 | |
| |
| Sucampo Pharmaceuticals, Inc. |
| Consolidated Balance Sheets (unaudited) |
| (in thousands, except share data) |
| | September 30, | | December 31, |
| | 2009 | | 2008 |
| ASSETS: | | | | |
| | | | |
| Current assets: | | | | |
| Cash and cash equivalents | | $ | 31,751 | | $ | 11,536 |
| Investments, current | | | 53,038 | | | 93,776 |
| Product royalties receivable | | | 9,368 | | | 9,725 |
| Unbilled accounts receivable | | | 828 | | | 4,373 |
| Accounts receivable | | | 1,350 | | | 878 |
| Prepaid and income taxes receivable | | | - | | | 133 |
| Deferred tax assets, net | | | 190 | | | 963 |
| Prepaid expenses and other current assets | | | 3,447 | | | 3,641 |
| Total current assets | | | 99,972 | | | 125,025 |
| | | | |
| Investments, non-current | | | 38,853 | | | 16,222 |
| Property and equipment, net | | | 2,357 | | | 2,275 |
| Deferred tax assets, non-current | | | 4,216 | | | 4,026 |
| Other assets | | | 4,339 | | | 3,246 |
| Total assets | | $ | 149,737 | | $ | 150,794 |
| | | | |
LIABILITIES AND STOCKHOLDERS' EQUITY: | | | | |
| | | | |
| Current liabilities: | | | | |
| Accounts payable | | $ | 2,122 | | $ | 1,433 |
| Accrued expenses | | | 9,414 | | | 9,764 |
| Deferred revenue, current | | | 13,499 | | | 15,599 |
| Income taxes payable | | | 313 | | | - |
| Total current liabilities | | | 25,348 | | | 26,796 |
| | | | |
| Deferred revenue, non-current | | | 10,217 | | | 8,061 |
| Other liabilities | | | 2,110 | | | 2,147 |
| Total liabilities | | | 37,675 | | | 37,004 |
| | | | |
Commitments | | | | |
| | | | |
| Stockholders' equity: | | | | |
Preferred stock, $0.01 par value; $5,000,000 shares authorized at September 30, 2009 and December 31, 2008; no shares issued and outstanding at September 30, 2009 and December 31, 2008 | | | - | | | - |
Class A common stock, $0.01 par value; 270,000,000 shares authorized at September 30, 2009 and December 31, 2008; 15,654,258 and 15,651,849 shares issued and outstanding at September 30, 2009 and December 31, 2008, respectively | | | 156 | | | 156 |
Class B common stock, $0.01 par value; 75,000,000 shares authorized at September 30, 2009 and December 31, 2008; 26,191,050 shares issued and outstanding at September 30, 2009 and December 31, 2008, respectively | | | 262 | | | 262 |
Additional paid-in capital | | | 98,516 | | | 98,243 |
| Accumulated other comprehensive income | | | 454 | | | 354 |
| Retained earnings | | | 12,674 | | | 14,775 |
| Total stockholders' equity | | | 112,062 | | | 113,790 |
| Total liabilities and stockholders' equity | | $ | 149,737 | | $ | 150,794 |
| |
| Sucampo Pharmaceuticals, Inc. |
| Key Segment Information (unaudited) |
| (in thousands) |
| |
| |
| | | | | | | | Intercompany | | |
| | Americas | | Europe | | Asia | | Eliminations | | Consolidated |
| Three Months Ended September 30, 2009 | | | | | | | | | | |
| Research and development revenue | | $ | 3,562 | | | $ | - | | | $ | 3,483 | | | $ | - | | | $ | 7,045 | |
| Product royalty revenue | | | 9,367 | | | | - | | | | - | | | | - | | | | 9,367 | |
| Co-promotion revenue | | | 1,266 | | | | - | | | | - | | | | - | | | | 1,266 | |
| Contract and collaboration revenue | | | 141 | | | | - | | | | 282 | | | | (270 | ) | | | 153 | |
| Total revenues | | | 14,336 | | | | - | | | | 3,765 | | | | (270 | ) | | | 17,831 | |
| Research and development expenses | | | 3,040 | | | | 459 | | | | 3,884 | | | | - | | | | 7,383 | |
| Depreciation and amortization | | | 213 | | | | 3 | | | | 7 | | | | - | | | | 223 | |
| Other operating expenses | | | 7,790 | | | | 1,029 | | | | 256 | | | | (270 | ) | | | 8,805 | |
| Income (loss) from operations | | | 3,293 | | | | (1,491 | ) | | | (382 | ) | | | - | | | | 1,420 | |
| Interest income | | | 277 | | | | - | | | | 2 | | | | (68 | ) | | | 211 | |
| Other non-operating expense, net | | | (17 | ) | | | (22 | ) | | | (279 | ) | | | 68 | | | | (250 | ) |
| Income (loss) before income taxes | | $ | 3,553 | | | $ | (1,513 | ) | | $ | (659 | ) | | $ | - | | | $ | 1,381 | |
| Capital expenditures | | $ | 64 | | | $ | - | | | $ | 87 | | | $ | - | | | $ | 151 | |
| | | | | | | | | | |
| Three Months Ended September 30, 2008 | | | | | | | | | | |
| Research and development revenue | | $ | 5,436 | | | $ | - | | | $ | - | | | $ | - | | | $ | 5,436 | |
| Product royalty revenue | | | 7,718 | | | | - | | | | - | | | | - | | | | 7,718 | |
| Co-promotion revenue | | | 1,185 | | | | - | | | | - | | | | - | | | | 1,185 | |
| Contract and collaboration revenue | | | 142 | | | | - | | | | 213 | | | | (213 | ) | | | 142 | |
| Total revenues | | | 14,481 | | | | - | | | | 213 | | | | (213 | ) | | | 14,481 | |
| Research and development expenses | | | 10,217 | | | | 330 | | | | 843 | | | | - | | | | 11,390 | |
| Depreciation and amortization | | | 110 | | | | 1 | | | | 3 | | | | - | | | | 114 | |
| Other operating expenses | | | 7,602 | | | | 139 | | | | 257 | | | | (210 | ) | | | 7,788 | |
| Income (loss) from operations | | | (3,448 | ) | | | (470 | ) | | | (890 | ) | | | (3 | ) | | | (4,811 | ) |
| Interest income | | | 678 | | | | 1 | | | | 2 | | | | (26 | ) | | | 655 | |
| Other non-operating expense, net | | | (6 | ) | | | (17 | ) | | | (21 | ) | | | 29 | | | | (15 | ) |
| Income (loss) before income taxes | | $ | (2,776 | ) | | $ | (486 | ) | | $ | (909 | ) | | $ | - | | | $ | (4,171 | ) |
| Capital expenditures | | $ | 5 | | | $ | 35 | | | $ | - | | | $ | - | | | $ | 40 | |
| | | | | | | | | | |
| Nine Months Ended September 30, 2009 | | | | | | | | | | |
| Research and development revenue | | $ | 12,539 | | | $ | - | | | $ | 7,427 | | | $ | - | | | $ | 19,966 | |
| Product royalty revenue | | | 27,227 | | | | - | | | | - | | | | - | | | | 27,227 | |
| Co-promotion revenue | | | 3,406 | | | | - | | | | - | | | | - | | | | 3,406 | |
| Contract and collaboration revenue | | | 424 | | | | - | | | | 717 | | | | (690 | ) | | | 451 | |
| Total revenues | | | 43,596 | | | | - | | | | 8,144 | | | | (690 | ) | | | 51,050 | |
| Research and development expenses | | | 16,398 | | | | 788 | | | | 9,783 | | | | - | | | | 26,969 | |
| Depreciation and amortization | | | 512 | | | | 9 | | | | 11 | | | | - | | | | 532 | |
| Other operating expenses | | | 20,851 | | | | 1,659 | | | | 1,803 | | | | (690 | ) | | | 23,623 | |
| Income (loss) from operations | | | 5,835 | | | | (2,456 | ) | | | (3,453 | ) | | | - | | | | (74 | ) |
| Interest income | | | 928 | | | | - | | | | 4 | | | | (190 | ) | | | 742 | |
| Other non-operating expense, net | | | 191 | | | | (392 | ) | | | (25 | ) | | | 190 | | | | (36 | ) |
| Income (loss) before income taxes | | $ | 6,954 | | | $ | (2,848 | ) | | $ | (3,474 | ) | | $ | - | | | $ | 632 | |
| Capital expenditures | | $ | 3,259 | | | $ | 3 | | | $ | 116 | | | $ | - | | | $ | 3,378 | |
| | | | | | | | | | |
| Nine Months Ended September 30, 2008 | | | | | | | | | | |
| Research and development revenue | | $ | 66,982 | | | $ | - | | | $ | - | | | $ | - | | | $ | 66,982 | |
| Product royalty revenue | | | 24,699 | | | | - | | | | - | | | | - | | | | 24,699 | |
| Co-promotion revenue | | | 3,643 | | | | - | | | | - | | | | - | | | | 3,643 | |
| Contract and collaboration revenue | | | 425 | | | | - | | | | 630 | | | | (630 | ) | | | 425 | |
| Total revenues | | | 95,749 | | | | - | | | | 630 | | | | (630 | ) | | | 95,749 | |
| Research and development expenses | | | 29,976 | | | | 1,703 | | | | 3,858 | | | | - | | | | 35,537 | |
| Depreciation and amortization | | | 318 | | | | 1 | | | | 7 | | | | - | | | | 326 | |
| Other operating expenses | | | 25,348 | | | | 1,188 | | | | 679 | | | | (630 | ) | | | 26,585 | |
| Income (loss) from operations | | | 40,107 | | | | (2,892 | ) | | | (3,914 | ) | | | - | | | | 33,301 | |
| Interest income | | | 1,924 | | | | 6 | | | | 5 | | | | (73 | ) | | | 1,862 | |
| Other non-operating expense, net | | | (39 | ) | | | (30 | ) | | | (20 | ) | | | 73 | | | | (16 | ) |
| Income (loss) before income taxes | | $ | 41,992 | | | $ | (2,916 | ) | | $ | (3,929 | ) | | $ | - | | | $ | 35,147 | |
| Capital expenditures | | $ | 304 | | | $ | 35 | | | $ | 3 | | | $ | - | | | $ | 342 | |
CONTACT:
Sucampo Pharmaceuticals, Inc.
Kate de Santis, 240-223-3834
kdesantis@sucampo.com
or
Westwicke Partners, LLC
John Woolford, 443-213-0506
john.woolford@westwickepartners.com
